Trial Profile
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Onatasertib (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Celgene Corporation
- 27 Jul 2017 According to a celgene corporation media release, data from this trial is expected in second half of 2017.
- 11 May 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2017.